Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
When TEAD2 DNA-binding domain was fused with virus protein 16 transcriptional activation domain, it synergized with activated β-catenin to promote HB formation in vivo.
|
30794805 |
2019 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Transcriptomic analysis showed a strong correlation in gene expression between HB in the Yap1-β-catenin model and HB patient cohorts.
|
30863496 |
2019 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Correction: mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development.
|
31645895 |
2019 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, we demonstrate that β-catenin point mutants can also collaborate with YAP1 in HB development, albeit with a distinct molecular profile from the deletion mutant, which may have implications in both biology and therapy.
|
30794807 |
2019 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Wnt/beta-catenin pathway is one of the major developmental pathways and is believed to play an important role in the pathogenesis of HB and CSC formation.
|
31547062 |
2019 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we investigated the oncogenic properties of 14 different HB- and non-HB-associated β-catenin mutants encoded by Sleeping Beauty vectors following their delivery into the mouse liver by hydrodynamic tail-vein injection.
|
31597698 |
2019 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The β-catenin mutation is frequently observed in hepatoblastoma (HB), but the underlying mechanism by which Wnt/β-catenin signaling induces HB tumor formation is unknown.
|
31462641 |
2019 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, the role of other signaling pathways in hepatoblastoma in association with Wnt/β-catenin has also been described.
|
31511432 |
2019 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we identify lipocalin 2 (Lcn2) as a target of β-catenin and YAP1 in HB and show that serum Lcn2 values positively correlated with tumor burden.
|
29920228 |
2018 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Wnt/β-catenin pathway plays a central role in the pathogenesis of most hepatoblastomas (HBs), that is, up to 60-80% carry activating CTNNB1 mutations.
|
29446530 |
2018 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Also, niclosamide, a Food and Drug Administration approved antihelminth compound, could effectively inhibit HB cell growth in vitro and in vivo via downregulation of Dvl-2 and β-catenin expression.
|
29528187 |
2018 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that activation of Yes-associated protein (YAP) is a major molecular event in HB development, as activated YAP synergizes with mutant β-catenin to promote HB formation in mice (YAP/β-catenin).
|
29088718 |
2017 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
All 3 (100%) mixed epithelial and mesenchymal HBL harbored CTNNB1 mutation.
|
29079173 |
2017 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We detected nuclear β-catenin immunostaining in nearly all untreated HBs, including in fetal and embryonal epithelial components and in mesenchymal elements.
|
28277286 |
2017 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Nuclear β-catenin staining which is significantly common in embryonal elements in HB predicts shorter survival.
|
28631020 |
2017 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Nuclear β-catenin expression was significantly associated with membranous epithelial cell adhesion molecule (EpCAM) expression in hepatoblastoma tumor specimens.
|
28851352 |
2017 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
However, variable survival rates of 60-80% and debilitating chemotherapy sequelae argue for more informed treatment selection, which is not possible by grading the Wnt-β-catenin over activity present in most HBL tumors.
|
27910913 |
2016 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To address their roles in the pathogenesis of HB, we generated mice in which Myc and mutant β-catenin were targeted to immature cells of the developing mouse liver.
|
27734029 |
2016 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
By contrast, the expression levels of epithelial-cadherin (E-cadherin) and cytosolic accumulation of β-catenin, the two most prominent markers involved in epithelial-mesenchymal transition (EMT), were reduced in liver specimens from patients with metastatic HB compared with that of healthy adjacent control tissue.
|
25695679 |
2015 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We transfected the parental HuH6 hepatoblastoma cell line with a doxycycline-inducible shRNA against CTNNB1 (gene coding for β-catenin) to obtain an isogenic cell line pair with or without aberrant β-catenin signaling.
|
26715116 |
2015 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings suggested the activation of the Wnt pathway in HB, which was confirmed by immunohistochemical staining of the β-catenin in 42 HB tumors.
|
24912477 |
2014 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Whole-exome sequencing identified HB as a genetically very simple tumour (2.9 mutations per tumour) with recurrent mutations in ß-catenin (CTNNB1) (12/15 cases) and the transcription factor NFE2L2 (2/15 cases).
|
25135868 |
2014 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Small interfering RNA-mediated knockdown of Yap1 or β-catenin in hepatoblastoma cells reduced proliferation in an additive manner.
|
24837480 |
2014 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The current observation of a somatic CTNNB1 mutation in a hepatoblastoma from a patient with a germline GPC3 mutation supports the notion that the mutation in GPC3 may influence one of the initial steps in tumorigenesis and the progression to hepatoblastoma.
|
24459012 |
2014 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our data clearly identify protein stabilizing mutations of the β-catenin gene as a common feature of nested stromal epithelial tumors of the liver, similarly as in hepatoblastomas.
|
22749188 |
2012 |